Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing study

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 5, 2012, Pages 593-599

  Chen, Jianmeng ^a   Flexner, Charles ^a   Liberman, Rosa G ^b   Skipper, Paul L ^b   Louissaint, Nicolette A ^a   Tannenbaum, Steven R ^b   Hendrix, Craig W ^a   Fuchs, Edward J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

Microdose; Pharmacokinetics; Tenofovir diphosphate

Indexed keywords

CARBON 14; DRUG METABOLITE; TENOFOVIR DIPHOSPHATE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZIDOVUDINE; ZIDOVUDINE GLUCURONIDE; ZIDOVUDINE TRIPHOSPHATE; 3'-AZIDO-3'-DEOXYTHYMIDINE 5'-TRIPHOSPHATE; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBON; DIDEOXYNUCLEOTIDE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; PYRIMIDINE NUCLEOTIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE 5' TRIPHOSPHATE;

ACCELERATOR MASS SPECTROMETRY; ADULT; AREA UNDER THE CURVE; CD4+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MICRODOSE; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NONLINEAR SYSTEM; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STANDARD; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; YOUNG ADULT; ARTICLE; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL AVAILABILITY; CARBON RADIOISOTOPES; CD4-POSITIVE T-LYMPHOCYTES; DIDEOXYNUCLEOTIDES; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; ORGANOPHOSPHONATES; PHOSPHORYLATION; REVERSE TRANSCRIPTASE INHIBITORS; THYMINE NUCLEOTIDES; ZIDOVUDINE;

EID: 84873194551     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182717c98     Document Type: Conference Paper

References (33)

1. Boddy AV, Sludden J, Griffin M.J., et al Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res. 2007;13:4164-4169.
2. Gao L, Li J, Kasserra C., et al Precision and accuracy in the quantitative analysis of biological samples by accelerator mass spectrometry: application in microdose absolute bioavailability studies. Anal Chem. 2011; 83:5607-5616.
3. Yamane N, Tozuka Z, Kusama M., et al Clinical relevance of liquid chromatography tandem mass spectrometry as an analytical method in microdose clinical studies. Pharm Res. 2011;28:1963-1972.
4. Lappin G, Kuhnz W, Jochemsen R., et al Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther. 2006;80:203-215.
5. Kurihara C. Ethical, legal, and social implications (ELSI) of microdose clinical trials. Adv Drug Deliv Rev. 2011;63:503-510.
6. Chen J, Garner RC, Lee L.S., et al Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo. Clin Pharmacol Ther. 2010;88:796-800.
7. Lavie A, Schlichting I, Vetter I.R., et al The bottleneck in AZT activation. Nat Med. 1997;3:922-924.
8. Robbins BL, Srinivas RV, Kim C, et al Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucle-oside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), Bis (isopropyloxymethylcarbonyl)PMPA. Antimicrob Agents Chemother. 1998; 42:612-617.
9. Anderson PL, Zheng JH, King T, et al Concentrations of zidovudine-and lamivudine-triphosphate according to cell type in HIV-seronegative adults. AIDS. 2007;21:1849-1854.
10. Louissaint NA, Nimmagadda S, Fuchs E.J., et al Distribution of cell-free and cell-associated HIV surrogates in the colon after simulated receptive anal intercourse in men who have sex with men. J Acquir Immune Defic Syndr. 2011;59:10-17.
11. King T, Bushman L, Anderson P.L., et al Quantitation of zidovudine tri-phosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831:248-257.
12. King T, Bushman L, Kiser J., et al Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;843:147-156.
13. Liberman RG, Tannenbaum SR, Hughey B.J., et al An interface for direct analysis of (14)c in nonvolatile samples by accelerator mass spectro-metry. Anal Chem. 2004;76:328-334.
14. Naesens L, Bischofberger N, Augustijns P., et al Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)-9-(2- phosphonylmethoxypropyl)adenine in mice. Antimicrob Agents Chemother. 1998;42:1568-1573.
15. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43: 595-612.
16. van Kampen J.J., Reedijk ML, Burgers P.C., et al Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. PLoS One. 2010;5:e11409.
17. Ford J, Khoo SH, Back DJ The intracellular pharmacology of antiretro-viral protease inhibitors. J Antimicrob Chemother. 2004;54:982-990.
18. Ieiri I, Nishimura C, Maeda K., et al Pharmacokinetic and pharmacoge-nomic profiles of telmisartan after the oral microdose and therapeutic dose. Pharmacogenet Genomics. 2011;21:495-505.
19. Maeda K, Takano J, Ikeda Y., et al Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. Clin Pharmacol Ther. 2011;90:263-270.
20. Programme EUMAPP. Outcomes from EUMAPP-a study comparing in vitro, in silico, microdose and pharmacological dose pharmacokinetics. Available at: http://www.eumapp.com/pdfs/EUMAPP%20SUMMARY.pdf.
21. Jorajuria S, Dereuddre-Bosquet N, Becher F., et al ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indi-navir in infected human macrophages. Antivir Ther. 2004;9:519-528.
22. Koch K, Chen Y, Feng J.Y., et al Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleosides Nucleotides Nucleic Acids. 2009;28:776-792.
23. Topalis D, Alvarez K, Barral K., et al Acyclic phosphonate nucleotides and human adenylate kinases: impact of a borano group on alpha-P position. Nucleosides Nucleotides Nucleic Acids. 2008;27:319-331.
24. Baheti G, Kiser JJ, Havens P.L., et al Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Anti-microb Agents Chemother. 2011;55:5294-5299.
25. Patterson KB, Prince HA, Kraft E, et al Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3:112-114.
26. Gagnieu MC, Barkil ME, Livrozet J.M., et al Population pharmaco-kinetics of tenofovir in AIDS patients. J Clin Pharmacol. 2008;48: 1282-1288.
27. Bushman LR, Kiser JJ, Rower J.E., et al Determination of nucleoside analog mono-, di-, and tri-phosphates in cellular matrix by solid phase extraction and ultra-sensitive LC-MS/MS detection. J Pharm Biomed Anal. 2011;56:390-401.
28. Hawkins T, Veikley W, St Claire RL 3rd, et al. Intracellular pharmaco-kinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J Acquir Immune Defic Syndr. 2005;39:406-411.
29. Kiser JJ, Aquilante CL, Anderson P.L., et al Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;47:298-303.
30. Borroto-Esoda K., Vela JE, Myrick F, et al In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377-384.
31. Delaney WE 4th, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477.
32. Abdool Karim Q., Abdool Karim SS, Frohlich JA, et al Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
33. Myers GM, Mayer KH Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25:63-71.